Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as an injectable solution for intravenous use. It interferes with cell division and is employed in the treatment of certain solid tumors, primarily in adult patients with lung or breast cancer.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable logistics and dedicated technical support throughout the supply chain.

Vinorelbine is a Vinca alkaloid used primarily in the treatment of certain solid tumors. - Non‑small cell lung cancer: administered as part of combination chemotherapy to inhibit tumor growth. - Metastatic breast cancer: used to control disease progression in patients who have received prior therapy. - Other solid tumors: may be incorporated into regimens for advanced colorectal or ovarian cancers where standard options are limited. - Pediatric solid tumors: evaluated in clinical studies for select sarcomas and neuroblastoma, though use is off‑label. - Head and neck cancer: occasionally used in combination protocols for recurrent disease.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count leading to infection risk. - Anemia: decreased red blood cells causing fatigue. - Nausea: feeling of sickness often accompanied by vomiting. - Vomiting: expulsion of stomach contents. - Constipation: difficulty passing stools. - Fatigue: generalized lack of energy.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: life‑threatening low white blood cells. - Pulmonary toxicity: inflammation or fibrosis of lung tissue. - Peripheral neuropathy: nerve damage causing tingling or pain. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: arrhythmias or reduced heart function. - Hepatotoxicity: significant elevation of liver enzymes.

When using Navirel, clinicians should observe several precautionary measures to minimise risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate pulmonary status: screen for pre‑existing lung disease and monitor for respiratory symptoms. - Use caution in cardiac disease: avoid in patients with significant arrhythmias or heart failure. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: agents such as ketoconazole may increase vinorelbine toxicity. - Strong CYP3A4 inducers: drugs like rifampin can reduce therapeutic levels. - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics containing CYP3A4 activity: may alter drug clearance and require dose adjustment. - Live vaccines: immunosuppression from vinorelbine can increase risk of infection.